Progress in nonviral gene therapy for breast cancer and what comes next?

Bottai, Giulia; Truffi, Marta; Corsi, Fabio; Santarpia, Libero

doi:10.1080/14712598.2017.1305351

Cited by 37 publications

(24 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 20 ] The possibility of correcting defective genes and modulating gene expression through gene therapy has emerged as a promising treatment strategy for cancer. [ 21 ] Furthermore, the relevance of tumor immune microenvironment in supporting the oncogenic process has paved the way for novel immunomodulatory applications of gene therapy. [ 21 ] Gene editing is a potential approach to alter the human genome to treat genetic diseases, viral diseases, and cancer.…”

Section: Discussionmentioning

confidence: 99%

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis

Li¹,

Ma²,

Luo

et al. 2020

Medicine

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is one of the most lethal cancer, mainly attributing to its high tendency to metastasis. Mounting evidence has demonstrated that genes and microRNAs (miRNAs) are related to human cancer onset and progression including invasion and metastasis. An eligible gene dataset and an eligible miRNA dataset were downloaded from the Gene Expression Omnibus (GEO) database based our screening criteria. Differentially expressed genes (DE-genes) or DE-miRNAs for each dataset obtained by the R software package. The potential target genes of the top 10 DE-miRNAs were predicted by multiple databases. For annotation, visualization and integrated discovery, Metascape 3.0 was introduced to perform enrichment analysis for the DE-genes and the predicted target genes of the selected top 10 DE-miRNAs, including Pathway and Process Enrichment Analysis or protein–protein interaction enrichment analysis. The intersection of predicted target genes and DE-genes was taken as the final DE-genes. Then apply the predicted miRNAs-targets relationship of top 10 DE-miRNAs to the final DE-genes to gain more convinced DE-miRNAs, DE-genes and their one to one relationship. GSE19945 (miRNA microarray) and GSE40275 (gene microarray) datasets were selected and downloaded. 56 DE-miRNAs and 861 DE-genes were discovered. 297 miRNAs-targets relationships (284 unique genes) were predicted as the target of top 10 upregulating DE-miRNAs. 245 miRNAs-targets relationships (238 unique genes) were identified as the target of top 10 downregulating DE-miRNAs. The key results of enrichment analysis include protein kinase B signaling, transmembrane receptor protein tyrosine kinase signaling pathway, negative regulation of cell differentiation, response to growth factor, cellular response to lipid, muscle structure development, response to growth factor, signaling by Receptor Tyrosine Kinases, epithelial cell migration, cellular response to organic cyclic compound, Cell Cycle (Mitotic), DNA conformation change, cell division, DNA replication, cell cycle phase transition, blood vessel development, inflammatory response, Staphylococcus aureus infection, leukocyte migration, and myeloid leukocyte activation. Differential expression of genes-upstream miRNAs (RBMS3-hsa-miR-7–5p, NEDD9-hsa-miR-18a-5p, CRIM1-hsa-miR-18a-5p, TGFBR2-hsa-miR-9–5p, MYO1C-hsa-miR-9–5p, KLF4-hsa-miR-7–5p, EMP2-hsa-miR-1290, TMEM2-hsa-miR-18a-5p, CTGF-hsa-miR-18a-5p, TNFAIP3-hsa-miR-18a-5p, THBS1-hsa-miR-182–5p, KPNA2-hsa-miR-144–3p, GPR137C-hsa-miR-1–3p, GRIK3-hsa-miR-144–3p, and MTHFD2-hsa-miR-30a-3p) were identified in SCLC. RBMS3, NEDD9, CRIM1, KPNA2, GPR137C, GRIK3, hsa-miR-7–5p, hsa-miR-18a-5p, hsa-miR-144–3p, hsa-miR-1–3p along with the pathways included protein kinase B signaling, muscle structure development, Cell Cycle (Mitotic) and blood vessel development may gain a high chance to play a key role in the prognosis of SCLC, but more studies should be conducted to reveal it more clea...

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis

Li¹,

Ma²,

Luo

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…Numerous non-viral gene delivery systems for different types of nucleic acids (mainly pDNA, siRNA and miRNA) have been described to date [ 34 , 38 ]. Different applications for the development of novel anticancer genetic nanomedicines have similarly being explored, including suicide gene therapies, anti-angiogenic gene therapies, immunotherapies, restoration of oncosuppressor RNAs, or gene silencing of oncogenes, or specific non-coding RNAs (antagomirs), or proteins involved in resistance to chemo- and radio-therapies, anti-apoptotic proteins, epigenetic regulation, etc., as recently reviewed by Bottai et al [ 39 ]. The main preclinical studies of the different applications of nanoparticles for gene therapy reported successful in mice models are summarized in Table 1 (reporter genes and experiments referring to over expression/silencing of housekeeping genes are not included).…”

Section: Genetic Nanomedicines and The Main Challenges For Their Tmentioning

confidence: 97%

The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines

Gutiérrez-Lovera

Vázquez-Ríos

Guerra‐Varela

et al. 2017

Genes

View full text Add to dashboard Cite

In the last few decades, the field of nanomedicine applied to cancer has revolutionized cancer treatment: several nanoformulations have already reached the market and are routinely being used in the clinical practice. In the case of genetic nanomedicines, i.e., designed to deliver gene therapies to cancer cells for therapeutic purposes, advances have been less impressive. This is because of the many barriers that limit the access of the therapeutic nucleic acids to their target site, and the lack of models that would allow for an improvement in the understanding of how nanocarriers can be tailored to overcome them. Zebrafish has important advantages as a model species for the study of anticancer therapies, and have a lot to offer regarding the rational development of efficient delivery of genetic nanomedicines, and hence increasing the chances of their successful translation. This review aims to provide an overview of the recent advances in the development of genetic anticancer nanomedicines, and of the zebrafish models that stand as promising tools to shed light on their mechanisms of action and overall potential in oncology.

show abstract

“…CRISPR variants can be delivered virally or nonvirally with varying efficiencies and clinical safety. Viral transduction is more potent than its nonviral counterpart, but is also accompanied by immunological concerns and concerns of seamless genetic integration . Regarding gene disruption efficiency, it is still unclear what efficiency is necessary to have a positive therapeutic effect in vivo, as it is possible that the current efficacy is inadequate to make a significant impact.…”

Section: Perspectives and Future Directionsmentioning

confidence: 99%

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy

Mintz

Gao

et al. 2018

Adv. Biosys.

View full text Add to dashboard Cite

Molecularly, breast cancer represents a highly heterogenous family of neoplastic disorders, with substantial interpatient variations regarding genetic mutations, cell composition, transcriptional profiles, and treatment response. Consequently, there is an increasing demand for alternative diagnostic approaches aimed at the molecular annotation of the disease on a patient‐by‐patient basis and the design of more personalized treatments. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated (Cas) technology enables the development of such novel approaches. For instance, in diagnostics, the use of the RNA‐specific C2c2 system allows ultrasensitive nucleic acid detection and could be used to characterize the mutational repertoire and transcriptional breast cancer signatures. In disease modeling, CRISPR/Cas9 technology can be applied to selectively engineer oncogenes and tumor‐suppressor genes involved in disease pathogenesis. In treatment, CRISPR/Cas9 can be used to develop gene‐therapy, while its catalytically‐dead variant (dCas9) can be applied to reprogram the epigenetic landscape of malignant cells. As immunotherapy becomes increasingly prominent in cancer treatment, CRISPR/Cas9 can engineer the immune cells to redirect them against cancer cells and potentiate antitumor immune responses. In this review, CRISPR strategies for the advancement of breast cancer diagnostics, modeling, and treatment are highlighted, culminating in a perspective on developing a precision medicine‐based approach against breast cancer.

show abstract

Progress in nonviral gene therapy for breast cancer and what comes next?

Cited by 37 publications

References 118 publications

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis

The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy

Contact Info

Product

Resources

About